medetinib

Medetinib is a novel small-molecule tyrosine kinase inhibitor (TKI) being developed for the treatment of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML). It specifically targets the BCR-ABL fusion protein, an oncogenic tyrosine kinase that results from the reciprocal translocation between chromosomes 9 and 22. By inhibiting BCR-ABL, medetinib disrupts the signaling pathways that drive the uncontrolled proliferation of leukemic cells. The drug is administered orally as medetitinib sulfate and has been investigated in Phase 1 clinical trials in China to evaluate its safety, tolerability, and pharmacokinetics in patients with newly diagnosed CML in the chronic phase.

Other names

medetitinibmeditinibmedetitinib sulfate